G2/M Accumulation in Prostate Cancer Cell Line PC-3 is Induced by Cdc25 Inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) Quinoline-5, 8-dione (DA 3003-2)

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2012 Sep 21

PMID 22993588

Citations 1

Authors

Kaoru Nemoto

Affiliations

Soon will be listed here.

Abstract

Cdc25 phosphatases are dual-specific phosphatases that play a role in cell cycle progression. In many human cancers, Cdc25 phosphatases are overexpressed as compared with normal tissues. In addition, overexpression of Cdc25 phosphatases in prostate cancer is correlated with disease progression. The antiproliferative efficacy of Cdc25 phosphatase inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2) was investigated in the PC-3 asynchronous human prostate cancer cell line using a cell-based assay. The time course changes in cell cycle distribution and the modulation of cell cycle regulators after DA 3003-2 administration were analyzed using the MTT assay. We found that the relative IC(50) of DA 3003-2 was 2-fold lower as compared with its congener (2-mercaptoethanol)-3-methyl-1, 4-naphthoquinone (NSC 672121). Asynchronous PC-3 cells accumulated in the G2/M phase at 24 h after treatment with 10 μM DA 3003-2 or 20 μM NSC 672121, which represent IC(70) concentrations. Treatment of cells with DA 3003-2 caused hyperphosphorylation of Cdc2 tyr(15) in cyclin B(1) and cyclin A complexes. DA 3003-2 did not downregulate the protein expression levels of Cdc25s, cyclins and cyclin-dependent kinases (Cdks). To conclude, after DA 3003-2 administration asynchronous PC-3 cells accumulated in the G2/M phase, with hyperphosphorylation of the G2/M cyclin-Cdk complex.

Citing Articles

Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategies.

Sur S, Agrawal D Mol Cell Biochem. 2016; 416(1-2):33-46.

PMID: 27038604 PMC: 4862931. DOI: 10.1007/s11010-016-2693-2.

References

Ngan E, Hashimoto Y, Ma Z, Tsai M, Tsai S . Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene. 2003; 22(5):734-9. DOI: 10.1038/sj.onc.1206121. View

Mashal R, Lester S, Corless C, Richie J, Chandra R, Propert K . Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res. 1996; 56(18):4159-63. View

Tamura K, Southwick E, Kerns J, Rosi K, Carr B, Wilcox C . Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res. 2000; 60(5):1317-25. View

Balk S, Knudsen K . AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008; 6:e001. PMC: 2254330. DOI: 10.1621/nrs.06001. View

Lazo J, Aslan D, Southwick E, Cooley K, Ducruet A, Joo B . Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem. 2001; 44(24):4042-9. DOI: 10.1021/jm0102046. View

Boutros R, Lobjois V, Ducommun B . CDC25 phosphatases in cancer cells: key players? Good targets?. Nat Rev Cancer. 2007; 7(7):495-507. DOI: 10.1038/nrc2169. View

Ozen M, Ittmann M . Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res. 2005; 11(13):4701-6. DOI: 10.1158/1078-0432.CCR-04-2551. View

Brisson M, Nguyen T, Vogt A, Yalowich J, Giorgianni A, Tobi D . Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Mol Pharmacol. 2004; 66(4):824-33. DOI: 10.1124/mol.104.001784. View

Chiu Y, Han H, Leung S, Yuen H, Chau C, Guo Z . CDC25A functions as a novel Ar corepressor in prostate cancer cells. J Mol Biol. 2008; 385(2):446-56. DOI: 10.1016/j.jmb.2008.10.070. View

10.

Kallakury B, Sheehan C, Ambros R, Fisher H, Kaufman Jr R, Muraca P . Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol. 1998; 16(4):1302-9. DOI: 10.1200/JCO.1998.16.4.1302. View

11.

Pu L, Amoscato A, Bier M, Lazo J . Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione. J Biol Chem. 2002; 277(49):46877-85. DOI: 10.1074/jbc.M207902200. View

12.

Kristjansdottir K, Rudolph J . Cdc25 phosphatases and cancer. Chem Biol. 2004; 11(8):1043-51. DOI: 10.1016/j.chembiol.2004.07.007. View

13.

Chmelar R, Buchanan G, Need E, Tilley W, Greenberg N . Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer. 2006; 120(4):719-33. DOI: 10.1002/ijc.22365. View

14.

Lazo J, Wipf P . Is Cdc25 a druggable target?. Anticancer Agents Med Chem. 2008; 8(8):837-42. PMC: 2752834. DOI: 10.2174/187152008786847738. View

15.

Lazo J, Nemoto K, Pestell K, Cooley K, Southwick E, Mitchell D . Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol. 2002; 61(4):720-8. DOI: 10.1124/mol.61.4.720. View

16.

Maddison L, Huss W, Barrios R, Greenberg N . Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer. Prostate. 2004; 58(4):335-44. DOI: 10.1002/pros.10341. View